While still unproven, targeting AMPK represents an exciting new treatment option for TB combined with diabetes, with strong efficacy in animal models of TB driven by its support of healthy mitochondria, reduced inflammation, and regulation of autophagy and apoptosis (Madhavi et al., 2018). The gene discussed is PRKAB1; the disease is diabetes mellitus.